TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24709264
Drug: Resiquimod 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiquimod 0.01% gel
Study: 14697444
Drug: Sorbolene cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbolene cream (10% glycerin)
Study: 2670647
Drug: Famotidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (1 tablet of 40 mg at night)
Study: 2670647
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 tablets of 150 mg at night)
Study: 805649
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G, 4.8 million units IM in one session plus 1.0 g probenecide
Study: 805649
Drug: Tetracycline HCI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline HCI, 9 g over 4 days
Study: 805649
Drug: Trimethoprim, 80
Normalized name: Sulfamethoxazole-Trimethoprim, 80 mg-16 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim, 80 mg-sulfamethoxazole, 400 mg (TMP-SMX) six tablets once daily for 3 days
Study: 805649
Drug: TMP-SMX, six
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMX, six tablets twice on 1 day at a 6-hour interval
Study: 28945869
Drug: Prednisolone (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (37.5 mg/d)
Study: 25449342
Drug: CC with
Normalized name: BD Syringe 5cc with Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC with audio-visual feedback device
Study: 25449342
Drug: CC without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC without audio-visual feedback device
Study: 21480984
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (0.5 mg/kg) with sublingual midazolam (0.2 mg/kg)
Study: 21480984
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (0.5 mg/kg) with sublingual placebo
Study: 18477268
Drug: Mannitol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (0.5 g x kg(‐1) in pump prime)
Study: 15232337
Drug: Naltrexone in
Normalized name: naltrexone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone in combination with clonazepam
Study: 11382108
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding started in the 1st postoperative week
Study: 3118746
Drug: Nebulized atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized atropine methonitrate (anticholinergic bronchodilator)
Study: 3118746
Drug: Metaproterenol hydrochloride
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol hydrochloride (beta-adrenergic bronchodilator)
Study: 26323489
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 4 µg kg(‐1) (Group 2)
Study: 26323489
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 3 µg kg(‐1) (Group 1)
Study: 11127760
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone acetate / 10 microg ethinyl estradiol
Study: 11127760
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone acetate / 5 microg ethinyl estradiol
Study: 11127760
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg norethindrone acetate / 2.5 microg ethinyl estradiol
Study: 8450526
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (20 mg twice daily)
Study: 2412034
Drug: Ketanserin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (120 mg/day)
Study: 31364875
Drug: Synbiotic powder
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic powder containing Lactobacillus reuteri (108 CFU) and soluble fiber (4.3 g)
Study: 29717175
Drug: Ginger capsules
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger capsules
Study: 24559600
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate capsules
Study: 18494974
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation (diamond bur + 37% phosphoric acid) (Group 1)
Study: 7538703
Drug: HCR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCR therapy (hyperthermia combined with chemotherapy and irradiation)
Study: 7538703
Drug: CR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR therapy (chemo-radiotherapy)
Study: 7538703
Drug: HCR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCR therapy
Study: 7538703
Drug: CR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR therapy
Study: 2185968
Drug: Octreotide injections
Normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide injections (100 micrograms t.i.d.)
Study: 30679336
Drug: bupivacaine 13
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 13 mg with intrathecal fentanyl 20 µg (Group BF)
Study: 30679336
Drug: bupivacaine 13
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 13 mg (Group B)
Study: 21235787
Drug: rostafuroxin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin 0.05 mg/d
Study: 21235787
Drug: rostafuroxin 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin 0.15 mg/d
Study: 21235787
Drug: rostafuroxin (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin (combined dosage arms)
Study: 19208731
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g EAA/d for 3 months (supplemented treatment group)
Study: 17536125
Drug: Pistachio nut
Normalized name: pistachio nut
DrugBank: Pistachio (DB10559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio nut diet (15% of daily caloric intake)
Study: 10819701
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine hydrochloride, 0.1 mg/d
Study: 8632299
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 mg) preceded by ketoconazole
Study: 8632299
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 mg) preceded by placebo
Study: 22245724
Drug: Flax drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax drink (2.5 g of soluble fibers)
Study: 22245724
Drug: Flax tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax tablets (2.5 g of soluble fibers)
Study: 22245724
Drug: CONTROL (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONTROL (300 mL drink)
Study: 19914563
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments including surgery, chemotherapy, molecular therapy, radiation therapy, immunotherapy, and palliative therapy
Study: 18401903
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin 20 mg twice a day along with topical clindamycin (1%) and adapalene (0.1%) for 24 weeks
Study: 18401903
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin only
Study: 8543495
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g every 8 h, infusion or bolus)
Study: 8543495
Drug: Imipenem/cilastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1 g every 8 h, infusion)
Study: 30840384
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose antioxidant supplementation (vitamins and minerals) for 7.5 years
Study: 15796636
Drug: Personal construct
Normalized name: Alstonia constricta bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal construct group therapy
Study: 7805903
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg twice per day for 14 days
Study: 7805903
Drug: Trimethoprim 160
Normalized name: trimethoprim 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 160 mg-sulfamethoxazole 800 mg twice per day for 14 days
Study: 7179201
Drug: Indobufen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (200 mg b.i.d.)
Study: 22695241
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 5 postoperative days with additional oral intake ad libitum
Study: 22695241
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition alone
Study: 12469362
Drug: nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide 120 mg three times daily
Study: 12469362
Drug: glibenclamide 5
Normalized name: glibenclamide 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide 5 mg once or twice daily
Study: 11774671
Drug: 60 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mmol/L nitrous oxide
Study: 11774671
Drug: 60 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mmol/L nitrous oxide with estazolam
Study: 11774671
Drug: 40 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mmol/L nitrous oxide
Study: 11774671
Drug: 40 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mmol/L nitrous oxide with estazolam
Study: 2643282
Drug: Slow-release nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nicardipine (40 mg twice a day)
Study: 18271889
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice a day)
Study: 12579420
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 5 ml/kg
Study: 27988142
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg once daily for 10 weeks
Study: 27988142
Drug: Filgotinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib (all doses)
Study: 24165696
Drug: 0.5-mg etanercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg etanercept
Study: 24165696
Drug: 2.5-mg etanercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-mg etanercept
Study: 24165696
Drug: 12.5-mg etanercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5-mg etanercept
Study: 22204799
Drug: Melatonin (MT)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MT) 5 mg twice daily
Study: 22204799
Drug: Tryptophan (TRP)
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan (TRP) 250 mg twice daily
Study: 22204799
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily + placebo
Study: 11533324
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus acetazolamide (100 mg/kg/d) and furosemide (1 mg/kg/d)
Study: 9604144
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg/2 ml ampul)
Study: 9604144
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg/1 ml ampul)
Study: 9604144
Drug: Tramadol and
Normalized name: tramadol and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol and Morphine
Study: 8064075
Drug: Cetirizine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 15 mg twice daily for 3 weeks
Study: 31828287
Drug: 4gOBG (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4gOBG (10 g oat-bran)
Study: 31828287
Drug: 2gOBG (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2gOBG (3 g oat-bran)
Study: 31828287
Drug: 4gloMW (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4gloMW (10 g oat-bran plus β-glucanase)
Study: 31828287
Drug: CR (Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR (Cream of Rice)
Study: 30317337
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (1.5 gm)
Study: 21549568
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for glucose and triglyceride levels, anticholinergic side effects, medication serum levels, cholesterol lowering medications, and pre‐study antipsychotic medications
Study: 10334433
Drug: Omacor (n-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor (n-3 fatty acids) 5.1 g/day
Study: 8921101
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dexamethasone (group B; n = 27)
Study: 8921101
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dexamethasone (group C; n = 27)
Study: 759126
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate ointment
Study: 776090
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate cream
Study: 26013241
Drug: Chloramine gel
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramine gel (Perisolv™) applied locally followed by mechanical instrumentation
Study: 25227897
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with fluorouracil and levamisole (5‐FU/Lev)
Study: 24402038
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract (36 mg proanthocyanidins per day) taken twice daily for 1 year
Study: 24402038
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken twice daily for 1 year
Study: 18688212
Drug: Active cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active cannabis (1-8% Delta-9-tetrahydrocannabinol), four times daily for 5 consecutive days
Study: 15837996
Drug: Aprepitant regimen
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant regimen (day 1: APR 125 mg, OND 8 mg, dexamethasone 12 mg; days 2-3: APR 80 mg qd)
Study: 15837996
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (day 1: OND 8 mg, dexamethasone 20 mg; days 2-3: OND 8 mg bid)
Study: 12623503
Drug: High-dose polyestradiol
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose polyestradiol phosphate (PEP) 240 mg i.m. twice a month for 2 months and thereafter once a month
Study: 12623503
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen deprivation (CAD) with flutamide (Eulexin) 250 mg t.i.d. and triptorelin (Decapeptyl) 3.75 mg per month i.m. or bilateral orchidectomy
Study: 7696066
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg orally as premedication
Study: 2966613
Drug: Maprotiline 75
Normalized name: maprotiline 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 75 mg with alcohol (1 g/kg)
Study: 2966613
Drug: Doxepin 25
Normalized name: doxepin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 25 mg with alcohol (1 g/kg)
Study: 2966613
Drug: Zimeldine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimeldine 200 mg with alcohol (1 g/kg)
Study: 2966613
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with alcohol (1 g/kg)
Study: 28969615
Drug: Transdiagnostic internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic internet-delivered cognitive behaviour therapy (iCBT)
Study: 26289076
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction arm
Study: 26289076
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing regimen
Study: 23013236
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) 50 mg
Study: 23013236
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) 2-600 mg
Study: 20653672
Drug: Oxycodone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (15 mg orally)
Study: 20653672
Drug: Morphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (30 mg orally)
Study: 20353023
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine syndrome-differentiation therapy
Study: 16270722
Drug: Pranlukast, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast, 450 mg/day (n = 33)
Study: 16270722
Drug: Sustained released
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained released Theo, 200 mg/day (n = 34)
Study: 3285833
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg torasemide
Study: 30762487
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 100 × 10^6 ADMSCs
Study: 30762487
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of 100 × 10^6 ADMSCs at baseline and 6 months
Study: 29855373
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg praziquantel (SAC)
Study: 29855373
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg praziquantel (SAC)
Study: 29855373
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg praziquantel (SAC)
Study: 29855373
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg praziquantel (PSAC)
Study: 29855373
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg praziquantel (PSAC)
Study: 26889911
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg daily (n=58)
Study: 23756717
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (pharmacological and cognitive behavioral therapy)
Study: 22437554
Drug: α-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-tocopherol (50 mg/d) supplementation
Study: 18818960
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (best medical management)
Study: 15090799
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and exercise training (1 hour of aerobic and resistance training three times a week)
Study: 9743817
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CS, Condrosulf, IBSA, Lugano, CH) 2 x 400 mg/day
Study: 8092558
Drug: Loratadine, 10
Normalized name: Loratadine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine, 10 mg once daily for 6 weeks
Study: 10328395
Drug: Propamidine isethionate
Normalized name: propamidine isethionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propamidine isethionate 0.1% ophthalmic solution (Brolene) and neomycin-polymyxin B-gramicidin ophthalmic solution (Neotricin)
Study: 8125424
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg/day)
Study: 2022303
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (30 ml containing 3.8 g EPA and 2.5 g DHA)
Study: 28408010
Drug: Avoidance of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoidance of treatment-related heart attack risk
Study: 28408010
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for treatment-related heart attack risk
Study: 25995282
Drug: High-Protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Protein (HP) snack (26 g of protein/6 g of fat per 27 g of carbohydrates)
Study: 25995282
Drug: High-Fat (HF)
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Fat (HF) snack (4 g of protein/12 g of fat per 32 g of carbohydrates)
Study: 24722445
Drug: 0.75 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/d atrasentan
Study: 24722445
Drug: 1.25 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/d atrasentan
Study: 24722445
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of atrasentan
Study: 24722445
Drug: Atrasentan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan (both doses)
Study: 22831874
Drug: Single, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral supplementation of 100,000 IU vitamin D3
Study: 17524997
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol gel at 1.25 g/day (0.75 mg/day)
Study: 17524997
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol gel at 2.5 g/day (1.5 mg/day)
Study: 17524997
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol gel at 5.0 g/day (3 mg/day)
Study: 17524997
Drug: Estriol 2
Normalized name: estriol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol 2 mg/day p.o. (control)
Study: 15545824
Drug: Methylprednisolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (15 mg/kg) added to the CPB priming solution (Group MP, n = 37)
Study: 11350567
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg o.d.)
Study: 10204735
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pethidine (P50)